TLRY:TSX-Tilray Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 4.02

Change

+0.01 (+0.25)%

Market Cap

CAD 1.93B

Volume

0.18M

Avg Analyst Target

CAD 13.04 (+224.34%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


TLRY Stock Forecast & Price:
Based on the Tilray Inc stock forecasts from 8 analysts, the average analyst target price for Tilray Inc is CAD 13.04 over the next 12 months. Tilray Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Tilray Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Tilray Inc’s stock price was CAD 4.02. Tilray Inc’s stock price has changed by -14.29% over the past week, -24.29% over the past month and -81.06% over the last year.

About Tilray Inc (TLRY:CA:TSX)

Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
BHC:CA Bausch Health Companies Inc

+0.15 (+1.39%)

CAD3.89B N/A 13.46
WEED:CA Canopy Growth Corp

-0.03 (-0.82%)

CAD1.47B N/A -19.25
CRON:CA Cronos Group Inc

+0.02 (+0.56%)

CAD1.35B 46.76 -0.59
GUD:CA Knight Therapeutics Inc

+0.06 (+1.12%)

CAD0.62B 41.51 12.98
ACB:CA Aurora Cannabis Inc

-0.01 (-0.59%)

CAD0.51B 1,171.00 -0.52
HLS:CA HLS Therapeutics Inc

-0.16 (-1.31%)

CAD0.40B N/A 18.13
OGI:CA OrganiGram Holdings Inc

+0.02 (+1.69%)

CAD0.37B -99,999.99 -132.30
DHT-UN:CA DRI Healthcare Trust

+0.19 (+2.55%)

CAD0.29B 9.91 N/A
TH:CA Theratechnologies Inc.

+0.01 (+0.34%)

CAD0.28B 954.70 -15.80

ETFs Containing TLRY:CA

Symbol Name Weight Mer Price(Change) Market Cap
HMMJ:CA Horizons Medical Marijuan.. 0.00 % 0.85 %

+0.04 (+1.15%)

CAD0.18B
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.85 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.93% 39% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.93% 39% F 4% F
Trailing 12 Months  
Capital Gain -81.21% 32% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.21% 32% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.93% 61% D- 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.93% 61% D- 13% F
Risk Return Profile  
Volatility (Standard Deviation) 12.29% 90% A- 59% F
Risk Adjusted Return -15.72% 58% F 18% F
Market Capitalization 1.93B 97% A+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.91 59% F 64% D
Price/Book Ratio 0.36 84% B 96% A
Price / Cash Flow Ratio -43.11 100% A+ 95% A
EV/EBITDA 11.67 13% F 26% F
Management Effectiveness  
Return on Equity 1.94% 84% B 34% F
Return on Invested Capital -18.07% 57% F 12% F
Return on Assets -2.70% 75% C 21% F
Debt to Equity Ratio 81.91% 14% F 35% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.91 63% D 43% F
Short Percent 1.17% 43% F 43% F
Beta 2.62 14% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector